Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titration Regimens in Young Adult and Elderly Participants With Schizophrenia and Healthy Elderly
NCT04506905Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elpipodect in schizophrenia (9 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) and Number of Participants Discontinuing Study Treatment Due to an AE. Started Aug 2020; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04506905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04506905.